5ª convocatoria IMI2
Se prevé que se abra la convocatoria a finales de junio y se cierre la primera fase a finales de septiembre.
Hasta el miércoles, 00 de de 0000
Han sido publicados los títulos de los topics.
1. Patient perspective elicitation on benefits and risks of medicinal products, supplementing benefit risk assessments by regulators and HTAs (health technology assessments) from development through the entire life cycle.
2. Development of a quantitative system toxicology (QST) platform.
3. Diabetic kidney disease (DKD) biomarker idea.
4. Inflammation and Alzheimer's disease (AD): modulating microglia function - focusing on TREM2 and CD33.
5. Enabling magnetic encephalography (MEG) as a biomarker for diagnosis and disease progression in mild cognitive impairment (MCI) and Alzheimer's disease (AD).
6. Understanding the role of amyloid biomarkers in diagnosis, clinical management and treatment of patients with cognitive impairment.
7. Evolving models of patient engagement and access for earlier identification of Alzheimer's disease.
8. Bringing apolipoprotein E (APOE) biology to validated Alzheimer's disease targets.
16/04/2015 11:12 | ralabort